217 related articles for article (PubMed ID: 38096768)
1. Progress and challenges in the translation of cancer nanomedicines.
Tong F; Wang Y; Gao H
Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
[TBL] [Abstract][Full Text] [Related]
2. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
[TBL] [Abstract][Full Text] [Related]
3. Organoids technology for advancing the clinical translation of cancer nanomedicine.
Zhao DK; Liang J; Huang XY; Shen S; Wang J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
[TBL] [Abstract][Full Text] [Related]
4. Cancer nanomedicine: progress, challenges and opportunities.
Shi J; Kantoff PW; Wooster R; Farokhzad OC
Nat Rev Cancer; 2017 Jan; 17(1):20-37. PubMed ID: 27834398
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Incorporated Nanomedicines for Cancer Therapy.
Wu SY; Wu FG; Chen X
Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
[TBL] [Abstract][Full Text] [Related]
6. Navigating zinc-involved nanomedicine in oncotherapy.
Yao J; Zhang A; Qiu Y; Li Z; Wu X; Li Z; Wu A; Yang F
Nanoscale; 2023 Mar; 15(9):4261-4276. PubMed ID: 36756840
[TBL] [Abstract][Full Text] [Related]
7. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
8. Inflammation targeted nanomedicines: Patents and applications in cancer therapy.
Praveen TK; Gangadharappa HV; Abu Lila AS; Moin A; Mehmood K; Krishna KL; Hussain T; Alafnan A; Shakil S; Rizvi SMD
Semin Cancer Biol; 2022 Nov; 86(Pt 2):645-663. PubMed ID: 35405339
[TBL] [Abstract][Full Text] [Related]
9. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology: Revolutionizing the Science of Drug Delivery.
Mishra M; Kumar P; Rajawat JS; Malik R; Sharma G; Modgil A
Curr Pharm Des; 2018; 24(43):5086-5107. PubMed ID: 30727873
[TBL] [Abstract][Full Text] [Related]
11. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
Balasubramanian V; Liu Z; Hirvonen J; Santos HA
Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
[TBL] [Abstract][Full Text] [Related]
12. Trends in Nanomedicines for Cancer Treatment.
do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
14. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
[TBL] [Abstract][Full Text] [Related]
15. Critical considerations for targeting colorectal liver metastases with nanotechnology.
Arshad U; Sutton PA; Ashford MB; Treacher KE; Liptrott NJ; Rannard SP; Goldring CE; Owen A
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1588. PubMed ID: 31566913
[TBL] [Abstract][Full Text] [Related]
16. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
17. Bridging Bio-Nano Science and Cancer Nanomedicine.
Björnmalm M; Thurecht KJ; Michael M; Scott AM; Caruso F
ACS Nano; 2017 Oct; 11(10):9594-9613. PubMed ID: 28926225
[TBL] [Abstract][Full Text] [Related]
18. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
[TBL] [Abstract][Full Text] [Related]
19. Clinical translation of nanomedicines: Challenges, opportunities, and keys.
Younis MA; Tawfeek HM; Abdellatif AAH; Abdel-Aleem JA; Harashima H
Adv Drug Deliv Rev; 2022 Feb; 181():114083. PubMed ID: 34929251
[TBL] [Abstract][Full Text] [Related]
20. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
Jiang Y; Jiang Z; Wang M; Ma L
Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
